Cargando…

The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study

BACKGROUND: Esophageal cancer (EC) is the sixth leading cause of tumor-related deaths worldwide. Estimates of the EC burden are necessary and could offer evidence-based suggestions for local cancer control. OBJECTIVE: The aim of this study was to predict the disease burden of EC in China through the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuanyuan, Xu, Junfang, Gu, Yuxuan, Sun, Xueshan, Dong, Hengjin, Chen, Changgui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928052/
https://www.ncbi.nlm.nih.gov/pubmed/34963658
http://dx.doi.org/10.2196/33191
_version_ 1784670573285081088
author Li, Yuanyuan
Xu, Junfang
Gu, Yuxuan
Sun, Xueshan
Dong, Hengjin
Chen, Changgui
author_facet Li, Yuanyuan
Xu, Junfang
Gu, Yuxuan
Sun, Xueshan
Dong, Hengjin
Chen, Changgui
author_sort Li, Yuanyuan
collection PubMed
description BACKGROUND: Esophageal cancer (EC) is the sixth leading cause of tumor-related deaths worldwide. Estimates of the EC burden are necessary and could offer evidence-based suggestions for local cancer control. OBJECTIVE: The aim of this study was to predict the disease burden of EC in China through the estimation of disability-adjusted life years (DALYs) and direct medical expenditure by sex from 2013 to 2030. METHODS: A dynamic cohort Markov model was developed to simulate EC prevalence, DALYs, and direct medical expenditure by sex. Input data were collected from the China Statistical Yearbooks, Statistical Report of China Children’s Development, World Population Prospects 2019, and published papers. The JoinPoint Regression Program was used to calculate the average annual percentage change (AAPC) of DALY rates, whereas the average annual growth rate (AAGR) was applied to analyze the changing direct medical expenditure trend over time. RESULTS: From 2013 to 2030, the predicted EC prevalence is projected to increase from 61.0 to 64.5 per 100,000 people, with annual EC cases increasing by 11.5% (from 835,600 to 931,800). The DALYs will increase by 21.3% (from 30,034,000 to 36,444,000), and the years of life lost (YLL) will account for over 90% of the DALYs. The DALY rates per 100,000 people will increase from 219.2 to 252.3; however, there was a difference between sexes, with an increase from 302.9 to 384.3 in males and a decline from 131.2 to 115.9 in females. The AAPC was 0.8% (95% CI 0.8% to 0.9%), 1.4% (95% CI 1.3% to 1.5%), and –0.7% (95% CI –0.8% to –0.7%) for both sexes, males, and females, respectively. The direct medical expenditure will increase by 128.7% (from US $33.4 to US $76.4 billion), with an AAGR of 5.0%. The direct medical expenditure is 2-3 times higher in males than in females. CONCLUSIONS: EC still causes severe disease and economic burdens. YLL are responsible for the majority of DALYs, which highlights an urgent need to establish a beneficial policy to reduce the EC burden.
format Online
Article
Text
id pubmed-8928052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-89280522022-03-18 The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study Li, Yuanyuan Xu, Junfang Gu, Yuxuan Sun, Xueshan Dong, Hengjin Chen, Changgui JMIR Public Health Surveill Original Paper BACKGROUND: Esophageal cancer (EC) is the sixth leading cause of tumor-related deaths worldwide. Estimates of the EC burden are necessary and could offer evidence-based suggestions for local cancer control. OBJECTIVE: The aim of this study was to predict the disease burden of EC in China through the estimation of disability-adjusted life years (DALYs) and direct medical expenditure by sex from 2013 to 2030. METHODS: A dynamic cohort Markov model was developed to simulate EC prevalence, DALYs, and direct medical expenditure by sex. Input data were collected from the China Statistical Yearbooks, Statistical Report of China Children’s Development, World Population Prospects 2019, and published papers. The JoinPoint Regression Program was used to calculate the average annual percentage change (AAPC) of DALY rates, whereas the average annual growth rate (AAGR) was applied to analyze the changing direct medical expenditure trend over time. RESULTS: From 2013 to 2030, the predicted EC prevalence is projected to increase from 61.0 to 64.5 per 100,000 people, with annual EC cases increasing by 11.5% (from 835,600 to 931,800). The DALYs will increase by 21.3% (from 30,034,000 to 36,444,000), and the years of life lost (YLL) will account for over 90% of the DALYs. The DALY rates per 100,000 people will increase from 219.2 to 252.3; however, there was a difference between sexes, with an increase from 302.9 to 384.3 in males and a decline from 131.2 to 115.9 in females. The AAPC was 0.8% (95% CI 0.8% to 0.9%), 1.4% (95% CI 1.3% to 1.5%), and –0.7% (95% CI –0.8% to –0.7%) for both sexes, males, and females, respectively. The direct medical expenditure will increase by 128.7% (from US $33.4 to US $76.4 billion), with an AAGR of 5.0%. The direct medical expenditure is 2-3 times higher in males than in females. CONCLUSIONS: EC still causes severe disease and economic burdens. YLL are responsible for the majority of DALYs, which highlights an urgent need to establish a beneficial policy to reduce the EC burden. JMIR Publications 2022-03-02 /pmc/articles/PMC8928052/ /pubmed/34963658 http://dx.doi.org/10.2196/33191 Text en ©Yuanyuan Li, Junfang Xu, Yuxuan Gu, Xueshan Sun, Hengjin Dong, Changgui Chen. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 02.03.2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on https://publichealth.jmir.org, as well as this copyright and license information must be included.
spellingShingle Original Paper
Li, Yuanyuan
Xu, Junfang
Gu, Yuxuan
Sun, Xueshan
Dong, Hengjin
Chen, Changgui
The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study
title The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study
title_full The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study
title_fullStr The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study
title_full_unstemmed The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study
title_short The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study
title_sort disease and economic burdens of esophageal cancer in china from 2013 to 2030: dynamic cohort modeling study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928052/
https://www.ncbi.nlm.nih.gov/pubmed/34963658
http://dx.doi.org/10.2196/33191
work_keys_str_mv AT liyuanyuan thediseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT xujunfang thediseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT guyuxuan thediseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT sunxueshan thediseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT donghengjin thediseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT chenchanggui thediseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT liyuanyuan diseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT xujunfang diseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT guyuxuan diseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT sunxueshan diseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT donghengjin diseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy
AT chenchanggui diseaseandeconomicburdensofesophagealcancerinchinafrom2013to2030dynamiccohortmodelingstudy